Ascendis Pharma A/S (Nasdaq: ASND) today announced new data showing improvements in growth and bone morphometry from Week 52 ...

In a new study published in Nature, researchers at the University of Chicago Medicine Comprehensive Cancer Center explore a ...

The potential of computational chemistry to revolutionise cancer treatment in Nigeria represents a paradigm shift in medical ...

Optimizing Radiotherapy Timing for Nasopharyngeal Carcinoma: The Impact of Radiation Scheduling on Survival FGFRi are effective treatment strategies for patients with advanced solid tumors harboring ...

C4 Therapeutics, Inc.’s CCCC share price has dipped by 6.01%, which has investors questioning if this is right time to buy.

The table below is a review of notable updates that occurred in April 2025 for investigational products in development (not an inclusive list). Click on the status to view our full coverage.

In the weeks to come, the European Commission will issue a decision on the first severe thyroid eye disease treatment.

After ten years, the risk of death was reduced by 17% for people treated with Perjeta (pertuzumab), Herceptin (trastuzumab), and chemotherapy (the Perjeta-based regimen) for a year as post-surgery ...

Swiss pharmaceutical company Roche has reported final overall survival outcomes from a long-term Phase III trial of Perjeta ...

Surrozen is a biotechnology company developing tissue-specific antibodies to selectively modulate the Wnt pathway, with a current focus on ophthalmology. Its proprietary technologies aim to harness ...

Black Diamond Therapeutics, Inc.’s BDTX share price has dipped by 5.39%, which has investors questioning if this is right ...